Stereotactic Body Radiotherapy Using CyberKnife® for Localized Low- and Intermediate-risk Prostate Cancer: Initial Report on a Phase I/II Trial

被引：3
|
作者：
Nakamura, Ryosuke [1 ]
Hirata, Takero [1 ]
Suzuki, Osamu [1 ]
Otani, Keisuke [1 ]
Kai, Naoki [1 ]
Hatano, Koji [2 ]
Fujita, Kazutoshi [2 ]
Uemura, Motohide [2 ]
Imamura, Ryoichi [2 ]
Tanaka, Kazunori [1 ]
Yoshioka, Yasuo [3 ]
Nonomura, Norio [2 ]
Ogawa, Kazuhiko [1 ]
机构：
[1] Osaka Univ, Grad Sch Med, Dept Radiat Oncol, 2-2 Yamada Oka, Suita, Osaka 5650871, Japan
[2] Osaka Univ, Grad Sch Med, Dept Urol, Osaka, Japan
[3] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Radiat Oncol, Tokyo, Japan
来源：
ANTICANCER RESEARCH | 2020年 / 40卷 / 04期
关键词：
SBRT; CyberKnife; prostate cancer; INTENSITY-MODULATED RADIOTHERAPY; FRACTIONATION; BRACHYTHERAPY;
D O I：
10.21873/anticanres.14162
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background: The present study aimed to evaluate the toxicity and efficacy of stereotactic body radiotherapy (SBRT) for localized prostate cancer. Patients and Methods: We investigated 25 patients treated with SBRT of 35 Gy per five fractions from May 2014 to March 2015. Results: The median age of patients was 70 years, four (16%) patients were low risk and 21 (84%) were intermediate risk. Seven (28%) patients received neoadjuvant androgen-deprivation therapy. The median follow-up time was 53 months. Grade 2 acute and late genitourinary toxicities were observed in five (20%) and two (8%) patients and there were no Grade 2 gastrointestinal toxicities. There were no Grade 3 or higher acute or late toxicities at 2 years follow-up. The biochemical relapse-free survival rate at 2 years was 100%. Conclusion: SBRT of 35 Gy per five fractions is a promising treatment method in the short term for prostate cancer.
引用
收藏
页码：2053 / 2057
页数：5
相关论文
共 50 条
  • [11] Outcomes of a Dose-Escalated Stereotactic Body Radiation Phase 1 Trial for Patients With Low- and Intermediate-Risk Prostate Cancer
    Potters, Louis
    Rana, Zaker
    Lee, Lucille
    Cox, Brett W.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 104 (02): : 334 - 342
  • [12] Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: Survival and Toxicity Endpoints
    Meier, Robert M.
    Bloch, Daniel A.
    Cotrutz, Cristian
    Beckman, Alan C.
    Henning, George T.
    Woodhouse, Shermian A.
    Williamson, Shirnett K.
    Mohideen, Najeeb
    Dombrowski, John J.
    Hong, Robert L.
    Brachman, David G.
    Linson, Patrick W.
    Kaplan, Irving D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (02): : 296 - 303
  • [13] SABR-Dual: a phase II/III trial of two-fraction versus five-fraction stereotactic radiotherapy for localized low- and favorable intermediate-risk prostate cancer
    Fredman, Elisha
    Icht, Oded
    Moore, Assaf
    Bragilovski, Dimitri
    Kindler, Jonathan
    Golan, Shay
    Limon, Dror
    BMC CANCER, 2024, 24 (01)
  • [14] SBRT in low- and intermediate-risk prostate cancer: results of a phase II study
    D'Agostino, G.
    Villa, E.
    Franzese, C.
    Liardo, R.
    Reggiori, G.
    Navarria, P.
    Iftode, C.
    De Rose, F.
    Franceschini, D.
    Tozzi, A.
    Comito, T.
    Ascolese, A.
    Tomatis, S.
    Scorsetti, M.
    RADIOTHERAPY AND ONCOLOGY, 2016, 119 : S628 - S629
  • [15] Toxicity and Quality of Life Report of a Phase 2 Study of Stereotactic Body Radiation Therapy (SBRT) for Low- and Intermediate-Risk Prostate Cancer
    Boyer, M. J.
    Rushing, C.
    Peterson, B.
    Papagikos, M. A.
    Kiteley, R. A.
    Lee, W. R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : E256 - E257
  • [16] A Phase II Trial of Stereotactic Body Radiotherapy Using 4 Fractions for Patients With Localized Prostate Cancer
    Kawakami, S.
    Hayakawa, T.
    Kainuma, T.
    Tsumura, H.
    Satoh, T.
    Tabata, K. I.
    Iwamura, M.
    Hayakawa, K.
    Ishiyama, H.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E275 - E275
  • [17] Long-term Outcomes from a Phase 1 Dose Escalation Study Using Stereotactic Body Radiotherapy for Patients with Low- or Intermediate-risk Prostate Cancer
    Moore, Assaf
    Kollmeier, Marisa A.
    Mcbride, Sean M.
    Toumbacaris, Nicolas
    Zhang, Zhigang
    Lacy-Elsayegh, Ahmed
    Dreyfuss, Alexandra
    Grossman, Craig E.
    Gorovets, Daniel
    Zelefsky, Michael J.
    EUROPEAN UROLOGY ONCOLOGY, 2024, 7 (04): : 812 - 820
  • [18] Pure Hypofractionated Radiotherapy for the Treatment of Low- to Intermediate-Risk Prostate Cancer
    Stephens, R.
    Gopaul, D.
    Panjwani, D.
    Lock, M.
    RADIOTHERAPY AND ONCOLOGY, 2017, 123 : S732 - S732
  • [19] Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer
    van As, Nicholas
    Griffin, Clare
    Tree, Alison
    Patel, Jaymini
    Ostler, Peter
    van der Voet, Hans
    Loblaw, Andrew
    Chu, William
    Ford, Daniel
    Tolan, Shaun
    Jain, Suneil
    Camilleri, Philip
    Kancherla, Kiran
    Frew, John
    Chan, Andrew
    Naismith, Olivia
    Armstrong, John
    Staffurth, John
    Martin, Alexander
    Dayes, Ian
    Wells, Paula
    Price, Derek
    Williamson, Emily
    Pugh, Julia
    Manning, Georgina
    Brown, Stephanie
    Burnett, Stephanie
    Hall, Emma
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (15): : 1413 - 1425
  • [20] Toxicity and quality of life report of a phase II study of stereotactic body radiotherapy (SBRT) for low and intermediate risk prostate cancer
    Matthew J. Boyer
    Michael A. Papagikos
    Rex Kiteley
    Zeljko Vujaskovic
    Jackie Wu
    W. Robert Lee
    Radiation Oncology, 12
12345